Skip to main content

The group's goal is to develop new targeted and personalised cancer immunotherapies. To this end, the group combines bioinformatics and molecular research to identify neoantigens and develop cancer vaccines based on these molecules

The Neoantigens and Vaccines against Cancer (NeoVaCan) group performs immunogenomic analyses of solid tumours and liquid biopsies to study the interplay between tumour cells and the immune microenvironment. Multi-omics coupled to functional T-cell-based assays is deployed to obtain a deeper understanding of the host immune response to cancer and to identify immune escape mechanisms.

A main pillar of the group’s work is to identify and characterize neoantigens (mutated peptides expressed only by tumour cells) to be used as targets for immunotherapies, with a special focus on neoantigen vaccines. NeoVaCan is, with the VIC group, co-developing preventive and therapeutic neoantigen vaccines using an in-house virus-like particle (VLP)-based vaccine platform.

Núria de la Iglesia Zaragoza
Principal investigator
Núria de la Iglesia Zaragoza
Dr Núria de la Iglesia graduated in Pharmacy at the University of Barcelona and completed her PhD on liver metabolism under the supervision of Dr. Joan Guinovart and Dr. Joan Carles Ferrer in 2001. In…
Go to profile
Not available in
This is not available in . You can go to the translated versions in these languages: